Comparative responsiveness of the EuroQol-5D and Short Form 6D to improvement in patients with rheumatoid arthritis treated with tumor necrosis factor blockers: Results of the Dutch Rheumatoid Arthritis Monitoring registry

Arthritis Care and Research

Volumn 64, Issue 6, 2012, Pages 826-832

  Buitinga, Laurien ^a   Braakman Jansen, Louise M A ^a   Taal, Erik ^a   Kievit, Wietske ^b   Visser, Henk ^c   Van Riel, Piet L C M ^b   Van De Laar, Mart A F J ^a  

^a UNIVERSITY OF TWENTE   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c RIJNSTATE HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANXIETY; ARTICLE; DEPRESSION; DISEASE ACTIVITY; EUROQOL 5D; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT MOBILITY; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; SELF CARE; SHORT FORM 6D; VISUAL ANALOG SCALE; COMPARATIVE STUDY; DISABILITY; DRUG ANTAGONISM; HOSPITALIZATION; METHODOLOGY; MIDDLE AGED; NETHERLANDS; OUTCOME ASSESSMENT; RECEIVER OPERATING CHARACTERISTIC; REGISTER; TREATMENT OUTCOME;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISABILITY EVALUATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY OF LIFE; REGISTRIES; ROC CURVE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84863186716     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.21619     Document Type: Article

References (35)

1. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81.
2. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400-11.
3. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987-97.
4. Zink A, Strangfeld A, Schneider M, Herzer P, Hierse F, Stoyanova-Scholz M, et al. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum 2006;54:3399-407.
5. Kievit W, Fransen J, Oerlemans AJ, Kuper HH, van der Laar MA, de Rooij DJ, et al. The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice. Ann Rheum Dis 2007;66:1473-8.
6. Harrison MJ, Davies LM, Bansback NJ, Ingram M, Anis AH, Symmons DP. The validity and responsiveness of generic utility measures in rheumatoid arthritis: a review. J Rheumatol 2008;35:592-602.
7. Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ 1986;5:1-30.
8. Smith MD, Drummond M, Brixner D. Moving the QALY forward: rationale for change. Value Health 2009;12:S1-4.
9. Cook KF, Ashton CM, Byrne MM, Brody B, Geraci J, Giesler RB, et al. A psychometric analysis of the measurement level of the rating scale, time trade-off, and standard gamble. Soc Sci Med 2001;53:1275-85.
10. Brooks R, de Charro F. EuroQol: the current state of play. Health Policy 1996;37:53-72.
11. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002;21:271-92.
12. Horsman J, Furlong W, Feeny D, Torrance G. The Health Utilities Index (HUI): concepts, measurement properties and applications. Health Qual Life Outcomes 2003;1:1-13.
13. Gold MR, Siegel JE, Russel LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
14. Guyatt G, Walter S, Norman G. Measuring change over time: assessing the usefulness of evaluative instruments. J Chronic Dis 1987;40:171-8.
15. Harrison MJ, Davies LM, Bansback NJ, McCoy MJ, Verstappen SM, Watson K, et al. The comparative responsiveness of the EQ-5D and SF-6D to change in patients with inflammatory arthritis. Qual Life Res 2009;18:1195-205.
16. Marra CA, Rashidi AA, Guh D, Kopec JA, Abrahamowicz M, Esdaile JM, et al. Are indirect utility measures reliable and responsive in rheumatoid arthritis patients? Qual Life Res 2005;14:1333-44.
17. Russell AS, Conner-Spady B, Mintz A. The responsiveness of generic health status measures as assessed in patients with rheumatoid arthritis receiving infliximab. J Rheumatol 2003;30:941-7.
18. Conner-Spady B, Suarez-Almazor ME. Variation in the estimation of quality-adjusted life-years by different preferencebased instruments. Med Care 2003;41:791-801.
19. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
20. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-108.
21. Lamers LM, Stalmeier PF, McDonnell J, Krabbe PF, van Busschbach JJ. Measuring the quality of life in economic evaluations: the Dutch EQ-5D tariff. Ned Tijdschr Geneeskd 2005;149:1574-8. In Dutch.
22. Ware JE Jr, Sherbourne CD. The MOS 36-item Short-Form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
23. Fitzpatrick R, Ziebland S, Jenkison C, Mowat A. Transition questions to assess outcomes in rheumatoid arthritis. Br J Rheumatol 1993;32:807-11.
24. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
25. Husted JA, Cook RJ, Farewell VT, Gladman DD. Methods for assessing responsiveness: a critical review and recommendations. J Clin Epidemiol 2000;53:459-68.
26. Cohen J. A power primer. Psychol Bull 1992;112:155-9.
27. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997;6:327-40.
28. Van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998;41:1845-50.
29. Swets JA. Measuring the accuracy of diagnostic systems. Science 1988;240:1285-93.
30. McHorney CA, Tarlov AR. Individual-patient monitoring in clinical practice: are available health status surveys adequate? Qual Life Res 1995;4:293-307.
31. Deyo RA, Diehr P, Patrick DL. Reproducibility and responsiveness of health status measures statistics and strategies for evaluation. Control Clin Trials 1991;12:S142-58.
32. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
33. Lloyd S, Bujkiewicz S, Wailoo AJ, Sutton AJ, Scott D. The effectiveness of anti-TNF-a therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta-analysis. Rheumatology (Oxford) 2010;49:2313-21.
34. Norman GR, Stratford P, Regehr G. Methodological problems in the retrospective computation of responsiveness to change: the lesson of Cronbach. J Clin Epidemiol 1997;50:869-79.
35. Hurst NP, Jobanputra P, Hunter M, Lambert M, Lochhead A, Brown H. Validity of Euroqol-a generic health status instrument-in patients with rheumatoid arthritis. Br J Rheumatol 1994;33:655-62.